非转移性前列腺癌原发局部治疗与非前列腺癌死亡的关联
基于加拿大安大略省2002至2009年人群的回顾性队列研究,将接受手术或放疗的非转移性前列腺癌患者按人口学、合并症和心血管危险因素匹配。共匹配5393对男性,放疗组10年非前列腺癌死亡累积发生率为12%,高于手术组的8%(校正亚分布风险比1.57,95%CI 1.35-1.83),放疗组心血管死亡风险亦升高(校正HR 1.74,95%CI 1.27-2.37)。
要点
- 匹配心血管危险因素后,放疗组非前列腺癌死亡风险仍高于手术组。
- 放疗组10年非前列腺癌死亡累积发生率为12%,手术组为8%。
- 放疗组心血管死亡校正HR为1.74(95%CI 1.27-2.37)。
核心结论
- 在心血管危险因素匹配的患者中,接受放疗者非前列腺癌死亡和心血管病风险增加。
- 由于数据为观察性,混杂可能性仍存在,但需较强且分布差异大的残余混杂才能消除观察到的效应。
研究设计与样本
- 人群基础的回顾性队列研究,纳入2002至2009年加拿大安大略省接受治疗的非转移性前列腺癌男性。
- 手术与放疗患者按人口学、合并症和心血管危险因素进行匹配,共分析5393对匹配男性。
主要发现
- 放疗组10年非前列腺癌死亡累积发生率为12%,手术组为8%(校正亚分布HR 1.57,95%CI 1.35-1.83)。
- 放疗组心血管死亡校正HR为1.74(95%CI 1.27-2.37)。
- 假设的残余混杂因素需与非前列腺癌死亡强关联(HR>2.5)且分布高度差异才能将观察效应归零。
关键数值与推荐
- 主要结局为非前列腺癌死亡,采用Fine和Gray亚分布方法及广义估计方程比较。
- 放疗组非前列腺癌死亡校正亚分布HR 1.57(95%CI 1.35-1.83),手术组为参照。
- 放疗组心血管死亡校正HR 1.74(95%CI 1.27-2.37)。
临床怎么用
- 原文未报告临床实践推荐。
局限性
- 原文自述数据为观察性,混杂可能性仍存在。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the association between local treatment modality, surgery or radiotherapy, and non-prostate cancer and cardiovascular mortality in patients treated for nonmetastatic prostate cancer, given the high competing risk of mortality in this population. METHODS: We performed a population-based, retrospective cohort study of men treated for nonmetastatic prostate cancer in Ontario, Canada, from 2002 to 2009. Patients treated with surgery and radiotherapy were matched on demographics, comorbidity, and cardiovascular risk factors. The primary outcome was non-prostate cancer mortality. Outcomes were compared using the Fine and Gray subdistribution method with generalized estimating equations. We used a previously published technique to quantify the prevalence and strength of residual confounding necessary to account for observed results. RESULTS: We examined 5393 pairs of matched men. The 10-year cumulative incidence of non-prostate cancer mortality was higher among patients who underwent radiotherapy (12%) than surgery (8%; adjusted subdistribution hazard ratio [HR] 1.57, 95% confidence interval 1.35-1.83). Patients treated with radiotherapy also had an increased risk of cardiovascular mortality (adjusted HR 1.74, 95% confidence interval 1.27-2.37). Hypothetical residual confounders would have to be both strongly associated with non-prostate cancer mortality (HRs > 2.5) and have highly differential prevalence to nullify the observed effect. CONCLUSION: Among patients carefully matched on cardiovascular risk factors, those treated with radiotherapy had an increased risk of non-prostate cancer mortality and cardiovascular disease. Because of the observational nature of the data, the potential for confounding remains. The magnitude and prevalence of potential residual confounders required to account for differences in treatment effects for prostate cancer was quantified.
引用
- Wallis CJD, Satkunasivam R, Herschorn S, et al. Association Between Primary Local Treatment and Non-prostate Cancer Mortality in Men With Nonmetastatic Prostate Cancer. Urology. 2018. PMID: 29305198. doi:10.1016/j.urology.2017.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。